Verge Genomics Named ‘Fierce 15’ Biotech for Novel Work in ALS

The treatment development company Verge Genomics — known for its all-in-human artificial intelligence platform — has been named among the “Fierce 15” by daily email newsletter Fierce Biotech.

Verge’s inclusion by the web resource in the 20th annual Fierce 15 listing, announced in a company press release, acknowledges its promise as an early-stage biotechnology company — one using artificial intelligence (AI) and human data to develop new therapies.

The biotech was one of the first companies to uncover PIKfyve, a novel target for amyotrophic lateral sclerosis (ALS), and to develop a treatment candidate in-house. That investigational ALS treatment is expected to begin clinical testing later this year, just four years after the target’s identification.